Investors with significant funds have taken a bearish position in Moderna MRNA, a development that retail traders should be aware of.
This was brought to our attention today through our monitoring of publicly accessible options data at Benzinga. The exact nature of these investors remains a mystery, but such a major move in MRNA usually indicates foreknowledge of upcoming events.
Today, Benzinga's options scanner identified 8 options transactions for Moderna. This is an unusual occurrence. The sentiment among these large-scale traders is mixed, with 25% being bullish and 75% bearish. Of all the options we discovered, 7 are puts, valued at $416,346, and there was a single call, worth $25,925.
Predicted Price Range
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $60.0 to $100.0 for Moderna over the last 3 months.
Insights into Volume & Open Interest
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Moderna's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Moderna's substantial trades, within a strike price spectrum from $60.0 to $100.0 over the preceding 30 days.
Moderna Option Volume And Open Interest Over Last 30 Days
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| MRNA | PUT | SWEEP | BULLISH | 05/17/24 | $90.00 | $118.3K | 121 | 913 |
| MRNA | PUT | SWEEP | BEARISH | 03/15/24 | $96.00 | $88.9K | 1.1K | 266 |
| MRNA | PUT | SWEEP | BEARISH | 01/17/25 | $60.00 | $59.2K | 3.4K | 268 |
| MRNA | PUT | TRADE | BEARISH | 03/08/24 | $100.00 | $46.3K | 384 | 0 |
| MRNA | PUT | SWEEP | BULLISH | 05/17/24 | $90.00 | $42.0K | 121 | 913 |
About Moderna
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
After a thorough review of the options trading surrounding Moderna, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
Current Position of Moderna
- With a volume of 1,872,027, the price of MRNA is down -3.73% at $93.85.
- RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.
- Next earnings are expected to be released in 63 days.
What Analysts Are Saying About Moderna
3 market experts have recently issued ratings for this stock, with a consensus target price of $100.66666666666667.
- An analyst from RBC Capital has revised its rating downward to Outperform, adjusting the price target to $125.
- An analyst from HSBC downgraded its action to Reduce with a price target of $86.
- Maintaining their stance, an analyst from Canaccord Genuity continues to hold a Hold rating for Moderna, targeting a price of $91.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Moderna with Benzinga Pro for real-time alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
